uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies
uBriGene Biosciences has partnered with Cellinfinity BIO to advance the clinical development of in vivo CAR-T therapy programmes for haematologic and solid tumours.
Read the full article on the original site.
Read Full Article